Showcasing India – South Africa Business Co-operation
Gufic Biosciences, a leading player in pharmaceutical and herbal products market, is now looking at tapping generics and high-end life-saving products segment in Africa, Asia and other regions. “The company is augmenting its global focus by deepening its presence in
Mylan NV announced Thursday that it had reached a deal with a Japanese drug company to offer a medication to treat a particularly virulent form of tuberculosis in developing countries. Financial terms of the deal weren’t announced between Mylan (Nasdaq:
Cipla Ltd, India`s fourth-largest drugmaker by sales, reported a 20 percent rise in quarterly profit, beating analysts` estimates, as higher sales in Europe and South Africa offset weakness in its key domestic market. Revenue from South Africa, Cipla`s third largest
In a recent survey conducted by India Connect it was found that the challenges faced by Indian Companies in South Africa mostly related to administrative issues such as short term insurance and matters involving staff benefits such as medical aid. Some
Popular spice turmeric may turn out to be a new weapon against tuberculosis, with Indian scientists discovering a set of wonder properties of the spice. Curcumin, the basic ingredient of turmeric, has been found to enhance the efficacy of standard
Ranbaxy Pharmaceuticals today announced recalling batches of its deworming medication Wormstop Suspension in South Africa. The company announced the recall in the national daily Business Report. “The reason for the recall is that the suspension does not flow easily from
Getting 36-year-old Eman Ahmed Abd El Aty to her hospital bed required the use of a cargo plane, a truck and a crane. “We took it in as a humanitarian cause to save a life and as a medical challenge,”
Production of drugs in SA instead of outsourcing to countries such as India would dent high unemployment Public-private partnerships in the pharmaceutical sector are vital for accelerating job creation and infrastructure development in SA, says malaria researcher Kelly Chibale. A
Drug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the production of biosimilars. The company’s “proposed biotech subsidiary in South Africa will invest just over R 1.3